SWORD Health (SWORD), a tech-enabled provider of musculoskeletal care, today announced the addition of $9 million to their Series A investment, bringing their total Series A investment to $17 million. The addition was led by Khosla Ventures, with participation from Founders Fund, Green Innovations, Lachy Groom, Vesalius Biocapital and Faber Ventures.
SWORD was founded in 2015, and has spent the last few years focused on developing and rigorously testing their therapeutic intervention in-market and clinically. The result is the only intervention in the musculoskeletal care space that treats preventive, chronic and post-surgical pain, and the only intervention clinically proven to outperform human therapists. In clinical trials, SWORD’s program outperformed one-on-one human physical therapy by 30%[1].
Founder and CEO Virgilio Bento said, “At SWORD, we’ve taken a disciplined and incremental approach to growth. Given the strong interest from the investment community and the demand we’re seeing in the market, we decided it was the right moment to expand.”
The additional capital will go towards increasing SWORD’s market footprint, investing in distribution, partnerships, sales and marketing, and making strategic product, clinical and operational investments to improve member experience and outcomes.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“SWORD’s digital clinical care model has been shown to significantly improve healthcare outcomes for patients while reducing employer costs, reshaping the future of physical therapy,” said Vinod Khosla, founder of Khosla Ventures. “This allows for very exciting options on innovative business models for the company.”
Delian Asparouhov, Principal at Founders Fund, said, “The opioid epidemic is a massive crisis in America, and significant portions of it are caused by musculoskeletal disorders being treated with painkillers. The ideal solution is preventative physical therapy, but current brick & mortar and telehealth options are prohibitively expensive — SWORD finally solves this and we are thrilled to partner with them.”
This extension follows the first closing of SWORD’s Series A led by Khosla Ventures in April 2019 and a Seed round of $4.6 million in April 2018, led by European VCs and angel investors. This latest raise brings SWORD Health’s total funding to $22 million since the company was founded in 2015.
Source: BioSpace